GT Biopharma Inc (GTBP): One year price target of $153. Published...

Reply Private New

Prev Next

Send PM Follow Ignore

Followers	0
Posts	7
Boards Moderated	0
Alias Born	01/26/2021

Otis T

Re: None

Thursday, 03/14/2024 11:56:44 AM

Thursday, March 14, 2024 11:56:44 AM

One year price target of $153. Published post split, article available on NASDAQ.com.

Keep Last Read

Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent GTBP News

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:46:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 05:15:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:30:39 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 10:00:11 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:25:12 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:23:32 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/06/2023 10:21:33 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 01:00:37 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 09:23:48 PM
Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 09/19/2023 03:56:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2023 08:55:28 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:29:58 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:26:31 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 01:00:11 PM

More GTBP News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover